JP2016537383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016537383A5 JP2016537383A5 JP2016532636A JP2016532636A JP2016537383A5 JP 2016537383 A5 JP2016537383 A5 JP 2016537383A5 JP 2016532636 A JP2016532636 A JP 2016532636A JP 2016532636 A JP2016532636 A JP 2016532636A JP 2016537383 A5 JP2016537383 A5 JP 2016537383A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- monoclonal antibody
- pharmaceutical composition
- cancer
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 108010062802 CD66 antigens Proteins 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 9
- 102000048362 human PDCD1 Human genes 0.000 claims 9
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 7
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 6
- 102000048119 human PDCD1LG2 Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 210000005168 endometrial cell Anatomy 0.000 claims 1
- 102000048776 human CD274 Human genes 0.000 claims 1
- 102000055639 human CEACAM3 Human genes 0.000 claims 1
- 102000047627 human CEACAM5 Human genes 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908190P | 2013-11-25 | 2013-11-25 | |
| US61/908,190 | 2013-11-25 | ||
| PCT/IL2014/051019 WO2015075725A1 (en) | 2013-11-25 | 2014-11-25 | Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221240A Division JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537383A JP2016537383A (ja) | 2016-12-01 |
| JP2016537383A5 true JP2016537383A5 (enExample) | 2018-01-11 |
| JP6879739B2 JP6879739B2 (ja) | 2021-06-02 |
Family
ID=53179065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532636A Active JP6879739B2 (ja) | 2013-11-25 | 2014-11-25 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
| JP2019221240A Pending JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019221240A Pending JP2020055853A (ja) | 2013-11-25 | 2019-12-06 | 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10081679B2 (enExample) |
| EP (2) | EP3074035B1 (enExample) |
| JP (2) | JP6879739B2 (enExample) |
| KR (1) | KR102362803B1 (enExample) |
| CN (1) | CN105744955B (enExample) |
| AU (1) | AU2014351308B2 (enExample) |
| CA (1) | CA2930218C (enExample) |
| ES (2) | ES2980417T3 (enExample) |
| HK (1) | HK1225998A1 (enExample) |
| MX (1) | MX375221B (enExample) |
| PL (2) | PL3763387T3 (enExample) |
| RU (1) | RU2697522C1 (enExample) |
| WO (1) | WO2015075725A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| US11427647B2 (en) * | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
| US10550196B2 (en) * | 2014-04-27 | 2020-02-04 | Famewave Ltd. | Humanized antibodies against CEACAM1 |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CN106699889A (zh) * | 2015-11-18 | 2017-05-24 | 礼进生物医药科技（上海）有限公司 | 抗pd-1抗体及其治疗用途 |
| CN107345968A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途 |
| CN107345969A (zh) * | 2016-05-05 | 2017-11-14 | 中国医学科学院基础医学研究所 | 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途 |
| EP3560957A4 (en) * | 2016-11-14 | 2020-10-21 | Dinona | ANTIBODIES BINDING SPECIFICALLY TO CD66C AND ASSOCIATED USE |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| CN106957823A (zh) * | 2016-12-28 | 2017-07-18 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l2蛋白单克隆抗体及其用途 |
| KR102019913B1 (ko) * | 2017-03-24 | 2019-09-09 | 재단법인 목암생명과학연구소 | 항-ceacam1 항체 및 이의 용도 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| EP3906261A4 (en) * | 2018-12-07 | 2022-12-21 | The Brigham And Women's Hospital, Inc. | HUMANIZED AND AFFINITY MATURED ANTI-CEACAM1 ANTIBODIES |
| JP2022514615A (ja) * | 2018-12-20 | 2022-02-14 | アルバート アインシュタイン カレッジ オブ メディスン | ヒト免疫チェックポイントＣＥＡＣＡＭ１（ＣＤ６６ａ）に対するアンタゴニスト抗体及びその製剤、キット並びに使用方法 |
| KR102166982B1 (ko) * | 2019-01-24 | 2020-10-16 | 가톨릭대학교 산학협력단 | 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법 |
| CA3132199A1 (en) * | 2019-03-12 | 2020-09-17 | President And Fellows Of Harvard College | Methods and compositions for treating cancer |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| EP4615871A1 (en) * | 2022-11-10 | 2025-09-17 | FameWave Ltd. | Anti carcinoembryonic antigen-related cell adhesion molecule 1 (ceacam1) antibodies for inhibition of neutrophil extracellular traps (net)-mediated activities |
| JP2025540021A (ja) * | 2022-12-07 | 2025-12-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド | 抗ｃｄ２４抗体及びｐｄ－１－ｐｄ－ｌ１経路遮断抗体を使用した癌に対する併用療法 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024151091A1 (ko) * | 2023-01-11 | 2024-07-18 | 한국과학기술원 | 종양 내 treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물 |
| WO2024213096A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Neologics Bioscience Co., Ltd. | Ceacam1-targeting antibodies and uses thereof |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| DE69309472T2 (de) | 1992-01-23 | 1997-10-23 | Merck Patent Gmbh, 64293 Darmstadt | Fusionsproteine von monomeren und dimeren von antikörperfragmenten |
| EP0787185A2 (en) | 1994-10-20 | 1997-08-06 | MorphoSys AG | Targeted hetero-association of recombinant proteins to multi-functional complexes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| CA2222055A1 (en) | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
| ES2246567T3 (es) | 1998-04-15 | 2006-02-16 | Brigham & Womens Hospital | Composiciones para receptores inhibidores de celulas t y usos de las mismas. |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| DE102008036127A1 (de) | 2008-08-01 | 2010-02-04 | Emitec Gesellschaft Für Emissionstechnologie Mbh | Verfahren zum Betrieb einer Abgasanlage mit Lambda-Regelung |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| US20120064100A1 (en) * | 2009-03-18 | 2012-03-15 | Simon Barry | Biomarkers and uses thereof |
| KR20180077322A (ko) * | 2009-04-30 | 2018-07-06 | 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드． | 항-ｃｅａｃａｍ1 항체들과 이를 이용하는 방법들 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2013054320A1 (en) * | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| HK1213788A1 (zh) * | 2012-10-12 | 2016-07-15 | 布里格姆及妇女医院股份有限公司 | 免疫應答的增强 |
-
2014
- 2014-11-25 PL PL20151989.9T patent/PL3763387T3/pl unknown
- 2014-11-25 AU AU2014351308A patent/AU2014351308B2/en not_active Ceased
- 2014-11-25 EP EP14863190.6A patent/EP3074035B1/en active Active
- 2014-11-25 EP EP20151989.9A patent/EP3763387B1/en active Active
- 2014-11-25 HK HK16114541.7A patent/HK1225998A1/zh unknown
- 2014-11-25 ES ES20151989T patent/ES2980417T3/es active Active
- 2014-11-25 PL PL14863190T patent/PL3074035T3/pl unknown
- 2014-11-25 WO PCT/IL2014/051019 patent/WO2015075725A1/en not_active Ceased
- 2014-11-25 RU RU2016124540A patent/RU2697522C1/ru active
- 2014-11-25 KR KR1020167015560A patent/KR102362803B1/ko active Active
- 2014-11-25 ES ES14863190T patent/ES2808684T3/es active Active
- 2014-11-25 CA CA2930218A patent/CA2930218C/en active Active
- 2014-11-25 MX MX2016006726A patent/MX375221B/es active IP Right Grant
- 2014-11-25 CN CN201480062823.5A patent/CN105744955B/zh active Active
- 2014-11-25 JP JP2016532636A patent/JP6879739B2/ja active Active
- 2014-11-25 US US15/039,022 patent/US10081679B2/en active Active
-
2019
- 2019-12-06 JP JP2019221240A patent/JP2020055853A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016537383A5 (enExample) | ||
| JP2020055853A5 (enExample) | ||
| JP2019510733A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| JP2017048240A5 (enExample) | ||
| JP2019524701A5 (enExample) | ||
| RU2016124540A (ru) | Композиции, содержащие анти-сеасам 1 и анти-pd антитела для терапии рака | |
| JP2018070648A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017500057A5 (enExample) | ||
| JP2021054859A5 (enExample) | ||
| IL253462B (en) | Cancer treatment with monoclonal antibodies against latency-associated peptide | |
| JP2017535257A5 (enExample) | ||
| EA202092460A1 (ru) | Антитела к ox40 и способы применения | |
| JP2018508483A5 (enExample) | ||
| JP2020534250A5 (enExample) | ||
| JP2018505674A5 (enExample) | ||
| JP2019535670A5 (enExample) | ||
| JP2015535828A5 (enExample) | ||
| JP2018512138A5 (enExample) | ||
| FI3799885T3 (fi) | Lymfosyyttien estoreittien neutralointi | |
| JP2013506428A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| HRP20201022T1 (hr) | Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba | |
| JP2014526898A5 (enExample) |